About: Vadimezan     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Vadimezan
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Organic Chemical
  • Pharmacologic Substance
Preferred_Name
  • Vadimezan
NSC_Code
  • 640488
UMLS_CUI
  • C0081181
CAS_Registry
  • 117570-53-3
FDA_UNII_Code
  • 0829J8133H
Contributing_Source
  • FDA
ALT_DEFINITION
  • An anticancer drug that is a type of angiogenesis inhibitor.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 43320
PDQ_Closed_Trial_Search_ID
  • 43320
Chemical_Formula
  • C17H14O4
Legacy_Concept_Name
  • Dimethylxanthenone_Acetic_Acid
FULL_SYN
  • dimethylxanthenone acetic acidPTNCI-GLOSSCDR0000046166
  • 5,6-Dimethylxanthenone-4-Acetic AcidSNNCI
  • DMXAAABNCI
  • ASA404CNNCI
  • VADIMEZANPTFDA0829J8133H
  • Dimethylxanthenone Acetic AcidSYNCI
  • VadimezanPTNCI
  • Dimethyloxoxanthene Acetic AcidSYNCI
  • 5,6-MexXAAABNCI
DEFINITION
  • A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.NCI
code
  • C2504
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 121 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software